Difference between revisions of "Complex multipart regimens"
Jump to navigation
Jump to search
(Created page with "The purpose of this page is to capture information about complex comparisons that is not easily conveyed on the treatment regimen pages. Many complex multipart RCTs are of the...") |
m (→Breast cancer) |
||
| Line 4: | Line 4: | ||
=Breast cancer= | =Breast cancer= | ||
| + | ==BCIRG-005== | ||
| + | ===Arm 1=== | ||
| + | *[[Breast_cancer#AC|AC]], then [[Breast_cancer#Paclitaxel_monotherapy_2|T]] | ||
| + | ===Arm 2=== | ||
| + | *[[Breast_cancer#TAC_.28Taxotere.29|TAC]] | ||
| + | ===Comparative efficacy=== | ||
| + | {| border="1" style="text-align:center;" !align="left" | ||
| + | |'''Schedule''' | ||
| + | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
| + | |- | ||
| + | |Concurrent (AC, then T) | ||
| + | |style="background-color:#ffffbf"|Seems not superior | ||
| + | |- | ||
| + | |Sequential (TAC) | ||
| + | |style="background-color:#ffffbf"|Seems not superior | ||
| + | |- | ||
| + | |} | ||
| + | ===References=== | ||
| + | # Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay MA, Riva A, Buyse M, Drevot P, Taupin H, Mackey JR. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011 Oct 10;29(29):3877-84. Epub 2011 Sep 12. [http://jco.ascopubs.org/content/29/29/3877.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21911726 PubMed] | ||
| + | |||
==CALGB 9741== | ==CALGB 9741== | ||
===Arm 1=== | ===Arm 1=== | ||
Revision as of 14:41, 9 December 2017
The purpose of this page is to capture information about complex comparisons that is not easily conveyed on the treatment regimen pages. Many complex multipart RCTs are of the "Y-shaped" format "A followed by B1 versus B2" or "A1 versus A2 followed by B" and this can be captured on the treatment regimen pages. This page will convey information on more complicated designs, such as "A followed by B versus B followed by A" or "A followed by B versus C followed by D".
Breast cancer
BCIRG-005
Arm 1
Arm 2
Comparative efficacy
| Schedule | Efficacy |
| Concurrent (AC, then T) | Seems not superior |
| Sequential (TAC) | Seems not superior |
References
- Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay MA, Riva A, Buyse M, Drevot P, Taupin H, Mackey JR. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011 Oct 10;29(29):3877-84. Epub 2011 Sep 12. link to original article contains verified protocol PubMed
CALGB 9741
Arm 1
- A, then T, then C
Arm 2
- ddA, then ddT, then ddC
Arm 3
Arm 4
Comparative efficacy
- Analyzed using a 2 x 2 factorial design
Comparison 1
| Dose density | Efficacy |
| Dose-dense (q2wk) | Seems to have superior OS |
| Standard (q3wk) | Seems to have inferior OS |
Comparison 2
| Schedule | Efficacy |
| Concurrent | Seems not superior |
| Sequential | Seems not superior |
References
- Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15;21(8):1431-9. Epub 2003 Feb 13. link to original article contains verified protocol PubMed